OCGN · Ocugen, Inc.
$1.30
-0.01 (-0.76%)
At close · Aug 5
Going-concern doubt
— flagged May 8, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these factors, together with the anticipated continued spending that will be necessary to continue to research, develop, and commercialize the Company's product candidates, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed May 8, 2026
Market Cap
$423.15M
Shares
338.52M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Shankar Musunuri | CEO | $4,841,822 |
| Huma Qamar | Chief Medical Officer | $2,888,481 |
| Arun Upadhyay | Chief Scientific Officer | $2,136,069 |
| Ramesh Ramachandran | Chief Accounting Officer | $1,192,089 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Shankar Musunuri | CEO | $1,941,538 |
| Huma Qamar | Chief Medical Officer | $1,725,701 |
| Arun Upadhyay | Chief Scientific Officer | $870,869 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Shankar Musunuri | CEO | $4,535,231 |
| Arun Upadhyay | Chief Scientific Officer | $1,384,076 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Shankar Musunuri | CEO | $8,141,351 |
| Sanjay Subramanian | CFO | $2,602,661 |
| Vijay Tammara | Senior Vice President, Regulatory & Quality | $1,307,585 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Shankar Musunuri | CEO | $1,552,178 |
| Sanjay Subramanian | CFO | $661,790 |
| Rasappa Arumugham | Chief Scientific Officer | $591,043 |
| Daniel Jorgensen | Chief Medical Officer | $537,139 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Adam Gridley | Former President | $768,937 |
| Shankar Musunuri | CEO | $572,320 |
| Stephen Kennedy | COO | $532,835 |
| Daniel Jorgensen | Chief Medical Officer | $432,303 |
| Donald Haut | Former Chief Business Officer | $410,968 |
| Rasappa Arumugham | Chief Scientific Officer | $365,358 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Adam Gridley | Former President | $664,121 |
| Daniel Jorgensen | Chief Medical Officer | $474,545 |
| Stephen Kennedy | COO | $466,031 |
| Shankar Musunuri | CEO | $431,000 |
| Rasappa Arumugham | Chief Scientific Officer | $418,795 |
| Donald Haut | Former Chief Business Officer | $417,851 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Ramesh Ramachandran | Chief Accounting Officer | Resigned | 2026-06-03 |
| Mohamed Genead, M.D., M.Sc. | Acting/Interim Chief Medical Officer | Appointed | 2026-05-14 |
| Rita Johnson-Greene | Chief Financial Officer | Appointed | 2026-02-09 |
| Prabha Fernandes, Ph.D., FIDSA | member of the Board of Directors | Resigned | 2025-04-25 |
| Ramesh Ramachandran | principal financial officer and principal accounting officer | Appointed | 2024-11-15 |
Key facts
CIK
1372299
CUSIP
67577C105
13F (30d)
34 filings
34 filers
Visit website
Investor relations